A Prospective, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of a Cream Containing Xyloglucan, Pea Protein, and

Stefano Veraldi, Valentina Rosca, Remus Ioan Orasan, Magda Constantin, Roni P Dodiuk-Gad

Open access · greenAbstract read

In one paragraph

Article in The Journal of clinical and aesthetic dermatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact, top 97% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 5 countries.

Stefano VeraldiDr. Veraldi is with the Dermatological Center in Milan, Italy.

Valentina RoscaDr. Rosca is with Emergency County Hospital in Targoviste, Romania.

Remus Ioan OrasanDr. Orasan is with Individual Medical Office of Dermatology in Cluj, Romania.

Magda ConstantinDr. Constantin is with Colentina Clinical Hospital in Bucharest, Romania.

Roni P Dodiuk-GadDr. Dodiuk-Gad is with the Department of Dermatology at Emek Medical Center in Afula, Israel, the Division of Dermatology and Department of Medicine at the University of Toronto in Toronto, Canada, and the Department of Dermatology and Bruce Rappaport Faculty of Medicine at the Technion Institute of Technology in Haifa, Israel.

County Hospital · GBIndividual Differences · USOspedale Monaldi · ITRappaport Family Institute for Research in the Medical Sciences · ILSpitalul Clinic Colentina · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Psoriasis is a chronic, inflammatory skin disease, requiring local and systemic drugs according to disease severity. This study aims to investigate the efficacy and safety of a topical treatment containing xyloglucan, pea proteins and Methods: Forty-two patients diagnosed with mild-to-moderate plaque psoriasis were assigned 1:1 to XPO treatment or CB for 28 days. Disease status was assessed at baseline (V1), monitored every two weeks (V2, V3), and at follow-up (V4). Disease severity was assessed by PASI (Psoriasis Area and Severity Index), PGA (Physician's Global Assessment), and VAS (Visual Analog Scale for itching). Photos were taken before and after XPO treatment. Treatment efficacy was determined by comparing psoriasis severity at baseline to V3. Tolerability was assessed by monitoring the occurrence of adverse events. Results: Both groups showed a statistically significant difference in PASI score from V1 to V2 ( Conclusion: XPO showed similar efficacy to CB, significantly reducing disease severity, erythema, itching, induration, and scaling with an excellent tolerability profile.

Indexed as

calcipotriol/betamethasoneOpuntia ficus-indica extractPASIpea proteinPsoriasisxyloglucan

Identifiers

PMID38495550

PMCPMC10941852

OpenAlexW4394759011

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.